We are live on ! Find out more
CNTA

Centessa Pharmaceuticals
CNTA

Delisted

CNTA was delisted on the 23rd of June, 2026.

Back to rankings

161 hedge funds and large institutions have $5.9B invested in Centessa Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 50 increasing their positions, 44 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more capital invested

Capital invested by funds: $3.6B → $5.9B (+$2.3B)

48% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 33

42% more funds holding in top 10

Funds holding in top 10: 12 → 17 (+5)

38% more call options, than puts

Call options by funds: $31.9M | Put options by funds: $23.2M

14% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 44

10% more funds holding

Funds holding: 146 → 161 (+15)

5.18% less ownership

Funds ownership: 106.95% → 101.77% (-5.2%)

Holders
161
Holders Change
+15
Holders Change %
+10.27%
% of All Funds
1.97%
Holding in Top 10
17
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+41.67%
% of All Funds
0.21%
New
49
Increased
50
Reduced
44
Closed
33
Calls
$31.9M
Puts
$23.2M
Net Calls
+$8.7M
Net Calls Change
+$4.77M

Top Buyers

Rank Fund Capital Flow
1
PCM
Pentwater Capital Management
Florida
+$209M
2
Capital World Investors
Capital World Investors
California
+$94M
3
PBA
Paradigm Biocapital Advisors
New York
+$91.4M
4
Morgan Stanley
Morgan Stanley
New York
+$80.8M
5
EC
EcoR1 Capital
California
+$73.8M

Top Sellers

Rank Fund Capital Flow
1
GA
General Atlantic
New York
-$122M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$98.2M
3
ACA
Avoro Capital Advisors
New York
-$79.9M
4
SL
Siren LLC
Connecticut
-$76.1M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$60.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
HF
76
HRT Financial
New York
$4.65M +$2.71M +105,972 +962%
Voloridge Investment Management
77
Voloridge Investment Management
Florida
$4.45M -$6.04M -236,323 -68%
FGP
78
Freestone Grove Partners
California
$4.34M +$2.8M +109,327 New
Legal & General Group
79
Legal & General Group
United Kingdom
$4.32M +$122K +4,780 +5%
Geode Capital Management
80
Geode Capital Management
Massachusetts
$4.28M +$516K +20,168 +23%
AA
81
AQR Arbitrage
Connecticut
$3.89M +$2.51M +98,028 New
YIH
82
Y-Intercept (HK)
Hong Kong
$3.83M +$2.17M +84,926 +742%
CIAM
83
Caitong International Asset Management
Hong Kong
$3.72M +$2.31M +90,467 +2,811%
HM
84
Harvest Management
New York
$3.18M +$2.05M +80,000 New
Citigroup
85
Citigroup
New York
$2.95M +$1.83M +71,585 +2,660%
JG
86
Jain Global
New York
$2.84M -$21.6M -844,290 -92%
VF
87
Virtu Financial
New York
$2.69M +$1.73M +67,775 New
Pictet Asset Management
88
Pictet Asset Management
Switzerland
$2.67M +$2.48M +96,910 New
Two Sigma Investments
89
Two Sigma Investments
New York
$2.38M +$61.4K +2,400 +4%
Squarepoint
90
Squarepoint
New York
$2.01M -$798K -31,206 -38%
WIC
91
Water Island Capital
New York
$1.63M +$1.05M +41,000 New
Jane Street
92
Jane Street
New York
$1.63M -$11.2M -439,236 -91%
BFM
93
Boothbay Fund Management
New York
$1.58M +$183K +7,148 +22%
DMKJ
94
David M. Knott Jr
$1.55M +$895K +35,000 +875%
Russell Investments Group
95
Russell Investments Group
United Kingdom
$1.54M -$921K -36,007 -48%
ACM
96
ADAR1 Capital Management
Texas
$1.53M – – –
CS
97
Candriam SCA
Luxembourg
$1.44M -$9.19M -359,369 -91%
BPMC
98
Buckland Partners Management Co
New York
$1.19M +$767K +30,000 New
VOYA Investment Management
99
VOYA Investment Management
Georgia
$1.18M – – –
CCM
100
Cinctive Capital Management
New York
$1.01M -$1.21M -47,481 -65%
2 3
4
5 6

CNTA Hedge Fund Activity: Q1 2026 in Review

161 of the 8,158 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q1 2026, worth a combined $5.9B — up 64% from $3.6B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new CNTA positions and 33 closed out — a net gain of 16 holders — while 50 added to existing stakes and 44 trimmed.

The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $209M. The largest seller was General Atlantic, cutting an estimated $122M.

  • 161 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q1 2026, up from 146 in Q4 2025.
  • Funds reported $5.9B of Centessa Pharmaceuticals stock for Q1 2026, up 64% quarter-over-quarter.
  • 49 funds opened new Centessa Pharmaceuticals positions in Q1 2026 and 33 closed out, a net change of +16 holders.
  • The largest Centessa Pharmaceuticals buyer in Q1 2026 was Pentwater Capital Management, an estimated $209M added.
  • The largest Centessa Pharmaceuticals seller in Q1 2026 was General Atlantic, an estimated $122M sold.

Based on aggregated 13F filings for Q1 2026.